UPDATE: Deutsche Bank Raises PT to $46 on Tenet Healthcare on Solid EBITDA Visibility

Deutsche Bank maintained Tenet Healthcare THC with a BUy rating and raised the price target from $43.00 to $46.00. Deutsche Bank noted, "We continue to believe THC has solid visibility into its 2013 EBITDA growth. Management is guiding to +14% yoy EBITDA growth at the mid-point of its $1.325 billion to $1.425 billion guidance range; DBe is $1.394 billion or +15.5% yoy. THC's visibility is enhanced by several tailwinds including: (1) a ~$35 million swing in HITECH income, net of HCIT implementation expense; (2) approximately $80 million of incremental savings from its Medicare performance initiative, which is designed to reduce variability in outcomes while reducing costs; (3) incremental EBITDA contributions from M&A and business development in the core business of $30M-$35M." Tenet Healthcare closed at $41.76 on Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsDeutsche Bank
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!